help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

Published ahead of print on January 25, 2007, doi:10.1164/rccm.200610-1436CP

Am. J. Respir. Crit. Care Med., Volume 175, Number 8, April 2007, 763-767

A more recent version of this article appeared on April 15, 2007
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
200610-1436CPv1
175/8/763    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McCall, C. E
Right arrow Articles by Yoza, B. K
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McCall, C. E
Right arrow Articles by Yoza, B. K

Submitted on October 8, 2006
Accepted on January 24, 2007

Gene Silencing in Severe Systemic Inflammation

Charles E McCall1* and Barbara K Yoza2

1 Sections of Molecular Medicine and Infectious Diseases, Department of Internal Medicine, Wake Forest University School of Medicine, Winston Salem, NC, USA, 2 Sections of Molecular Medicine and Infectious Diseases, Department of Internal Medicine, Wake Forest University School of Medicine, Winston Salem, NC, USA; Department of General Surgery, Division of Surgical Sciences, Wake Forest University School of Medicine, Winston Salem, NC, USA

* To whom correspondence should be addressed. E-mail: chmccall{at}wfubmc.edu.

This critical care perspective appraises reprogramming of gene expression in inflammatory diseases as an emerging concept of clinical importance. We emphasize gene reprogramming that 'silences' acute proinflammatory genes during severe systemic inflammation, wherein in the systemic inflammatory response syndrome (SIRS) exists as a continuum during severe sepsis, septic shock and the multiorgan dysfunction and failure phenotypes without infection In contrast, silencing of acute proinflammatory genes is not apparent in sites of localized inflammatory processes like rheumatoid arthritis. We discuss in three parts the clinical context and the translational basic science associated with gene silencing during the SIRS continuum of severe systemic inflammation: 1) reprogramming of acute proinflammatory genes; 2) an 'NF-BB paradox', coupled with RelB expression that combine to silence genes using an epigenetic (inherited and reversible) signature on the nucleosome; and 3) the potential clinical importance of compartmentalization in gene silencing. Our emergent understanding of these physiological processes may provide a novel framework developing treatments.


Key words: SIRS, NF kappa B, Transcription factor RelB, Nucleosomes, Respiratory Distress Syndrome, Adult, Inflammation




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
M. E. Gazzar, B. K. Yoza, J. Y.-Q. Hu, S. L. Cousart, and C. E. McCall
Epigenetic Silencing of Tumor Necrosis Factor {alpha} during Endotoxin Tolerance
J. Biol. Chem., September 14, 2007; 282(37): 26857 - 26864.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2007 American Thoracic Society